Treatment of systemic fungal infections in older patients: Achieving optimal outcomes

Drugs and Aging

Volumn 18, Issue 5, 2001, Pages 313-323

  Kauffman, Carol A ^b   Hedderwick, Sara A ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; CISAPRIDE; FLUCONAZOLE; FLUCYTOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TERFENADINE;

AGED; ANEMIA; ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG FORMULATION; HISTOPLASMOSIS; HUMAN; MUCORMYCOSIS; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RASH; REVIEW; SPOROTRICHOSIS; SYSTEMIC MYCOSIS;

EID: 0035012804     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118050-00002     Document Type: Review

References (62)

1. 1. Kauffman CA. Fungal infections. Clin Geriatr Med 1992; 8: 777-91
2. 2. Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29: 231-7
3. 3. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981-5
4. 4. Kauffman CA, Hajjeh R, Chapman S. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000; 30: 684-7
5. 5. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279-85
6. 6. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413-7
7. 7. Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22: 46-50
8. 8. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine 1986; 65: 143-53
9. 9. Bradsher RW. Clinical considerations in blastomycosis. Infect Dis Clin Pract 1992; 1: 97-104
10. 10. Chapman SW, Lin AC, Hendricks A, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997; 12: 219-28
11. 11. Kauffman CA. Endemic mycoses in older adults. Infect Dis Clin Pract 1995; 4: 41-5
12. 12. Chapman SW, Bradsher RW, Campbell GD, et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30: 679-83
13. 13. Dismukes WE, Bradsher RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489-97
14. 14. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20: 267-71
15. 15. Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher dose fluconazole. Clin Infect Dis 1997; 25: 200-5
16. 16. Dismukes WE, Cloud G, Bowles C, et al. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985; 103: 861-72
17. 17. Wheat J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997; 76: 339-54
18. 18. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688-95
19. 19. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23: 996-1001
20. 20. Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332: 1077-82
21. 21. Leake JAD, Mosley DG, England B, et al. Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996-1997. J Infect Dis 2000; 181: 1435-40
22. 22. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658-61
23. 23. Galgiani JN, Catanzaro A, Cloud GA, et al. Randomized double-blind comparison of oral fluconazole and itraconazole for progressive non-meningeal coccidioidomycosis. Ann Intern Med 2000; 133: 676-86
24. 24. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119: 28-35
25. 25. Dewsnup DH. Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124: 305-10
26. 26. Kauffman CA, Hedderwick S. Opportunistic fungal infections: filamentous fungi and cryptococcosis. Geriatrics 1997; 52: 40-9
27. 27. Stockstill MT, Kauffman CA. A comparison of tuberculous and cryptococcal meningitis. Arch Neurol 1983; 40: 81-5
28. 28. Hajjeh RA, Conn LA. Stephens DS. et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179: 449-54
29. 29. Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis. Arch Neurol 1984; 41: 216-7
30. 30. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115: 737-40
31. 31. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis. In press
32. 32. Saag MS, Graybill JR, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-8
33. 33. Hedderwick S, Kauffman CA. Opportunistic fungal infections: superficial and systemic candidiasis. Geriatrics 1997; 52: 50-9
34. 34. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70
35. 35. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511
36. 36. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995; 155: 2429-35
37. 37. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8
38. 38. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886-9
39. 39. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78
40. 40. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30
41. 41. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30: 14-8
42. 42. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30: 19-24
43. 43. Jacobs LG. Fungal urinary tract infections in the elderly: treatment guidelines. Drugs Aging 1996; 8: 89-96
44. 44. Leu H-S, Huang C-T. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20: 1152-7
45. 45. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805
46. 46. Binder RE, Faling J, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61: 109-24
47. 47. Washburn RG, Kennedy DW, Begley MG, et al. Chronic fungal sinusitis in apparently normal hosts. Medicine (Baltimore) 1988; 67: 231-47
48. 48. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709
49. 49. Hiemenz JR, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 Suppl. 2: S133-44
50. 50. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-6
51. 51. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol 1997; 39: 143-89
52. 52. Como JA. Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72
53. 53. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653-7
54. 54. Barone JA, Moscovitz BL, Guarnieri J, et al. Enhanced bio-availability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-5
55. 55. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19: 603-11
56. 56. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-61
57. 57. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-18
58. 58. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96
59. 59. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302
60. 60. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71
61. 61. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7
62. 62. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmaco-economic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476-83